Skip to main content

Advertisement

Figure 2 | BMC Research Notes

Figure 2

From: Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat

Figure 2

Effect of losartan (30 mg/kg/day) on the activated hepatic stellate cells in the OLETF rats. (A): Representative features of α-SMA-positive activated hepatic stellate cells in the liver of CDAA-treated OLETF rats. (B): Densitometric analysis of α-SMA-positive cells. The α-SMA-positive cells were significantly suppressed by treatment with losartan almost in parallel with reduction of liver fibrosis development. The data represent the mean ± SD (n = 5). *: Statistically significance between the indicated group (p < 0.01).

Back to article page